Related references
Note: Only part of the references are listed.OPTN/SRTR 2019 Annual Data Report: Kidney
A. Hart et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
LIMS1 risk genotype and T cell-mediated rejection in kidney transplant recipients
Yasar Caliskan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group
Carrie A. Schinstock et al.
TRANSPLANTATION (2020)
Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients
Dharmendra Jain et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Memory B Cells and Long-lived Plasma Cells
Lavinia Ionescu et al.
TRANSPLANTATION (2019)
Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases
Ek Khoon Tan et al.
TRANSPLANTATION (2019)
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Farsad Eskandary et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
An economic assessment of contemporary kidney transplant practice
David A. Axelrod et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Acute Antibody-Mediated Rejection and its Treatment in Kidney Transplantation: Report from a National Cohort Study
Nancy Perrottet et al.
TRANSPLANTATION (2018)
A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection
Philip S. Macklin et al.
TRANSPLANTATION REVIEWS (2017)
Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria
Robert R. Redfield et al.
HUMAN IMMUNOLOGY (2016)
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial
Benedicte Sautenet et al.
TRANSPLANTATION (2016)
Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study
Thomas Bachelet et al.
CLINICAL TRANSPLANTATION (2015)
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
M. Haas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy
Byung Ha Chung et al.
TRANSPLANT IMMUNOLOGY (2014)
Antibody-mediated vascular rejection of kidney allografts: a population-based study
Carmen Lefaucheur et al.
LANCET (2013)
Differential outcomes in 3 types of acute antibody-mediated rejection
Muhammad A. Rafiq et al.
CLINICAL TRANSPLANTATION (2009)
Immunoadsorption in severe C4d-positive acute kidney allograft rejection:: A randomized controlled trial
G. A. Boehmig et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barre syndrome
RK Lyu et al.
THERAPEUTIC APHERESIS (2002)
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients
RA Montgomery et al.
TRANSPLANTATION (2000)
Share Paper
